Search

Metastatic melanoma is an aggressive disease that still shows high mortality despite the recent discovery of immunotherapy and targeted therapy.1,2 The criteria currently known to influence a therapeutic response are mainly LDH, CRP and the number of metastatic sites.3 Overweight (body mass index (BMI) >= 25 kg/m SP 2 sp ) or obesity (BMI >= 30 kg/m SP 2 sp ) is currently a major public health issue. We carried out a retrospective study (2012-2017) whose aim was to determine whether a BMI >= 25 kg/m SP 2 sp was an early predictive factor of response in patients with metastatic melanoma treated in first line by targeted therapy or immunotherapy. We also demonstrate that BMI is an early prognostic factor for the response to treatment (6 months) in patients in first-line therapy. Our study shows that a high BMI is significantly associated with a better early therapeutic response in patients in first line of treatment particularly with targeted therapy and is an independent predictive factor. [Extracted from the article]